Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment

Jeremy Chien1, Rui Kuang, Charles Landen

  • 1Department of Cancer Biology, University of Kansas Medical Center , Kansas City, KS , USA.

Frontiers in Oncology
|September 27, 2013
PubMed

Insights

Ovarian cancer

Area of Science:

  • Oncology
  • Cancer Biology
  • Tumor Microenvironment Research

Background:

  • Ovarian cancer has a low survival rate despite advances in understanding its pathobiology.
  • Chemotherapy resistance significantly contributes to poor patient outcomes.
  • The tumor microenvironment, especially the extracellular matrix (ECM), is increasingly recognized for its role in treatment response.

Purpose of the Study:

  • To review the role of the tumor microenvironment in ovarian cancer recurrence.
  • To explore the impact of the tumor microenvironment on chemotherapy resistance.
  • To propose a new perspective on platinum-sensitive recurrence involving the ECM.

Main Methods:

  • Literature review of existing research on ovarian cancer pathobiology.
  • Analysis of studies focusing on tumor microenvironment components, including the extracellular matrix.
  • Synthesis of findings related to chemotherapy resistance mechanisms.

Main Results:

  • The tumor microenvironment plays a critical role in ovarian cancer's resistance to chemotherapy.
  • The extracellular matrix (ECM) is a key factor influencing treatment efficacy and recurrence.
  • Existing models of platinum-sensitive recurrence may not fully account for ECM's influence.

Conclusions:

  • Targeting the tumor microenvironment and ECM could offer new therapeutic strategies for ovarian cancer.
  • Understanding the ECM's role may lead to improved prediction and treatment of ovarian cancer recurrence.
  • A revised view of platinum-sensitive recurrence is proposed, emphasizing ECM interactions.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...